These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 20129554)

  • 1. Gone but not forgotten: the case for drug-eluting stents in percutaneous revascularization of the chronic coronary total occlusion.
    Tcheng JE; Zidar DA
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1266-8. PubMed ID: 20129554
    [No Abstract]   [Full Text] [Related]  

  • 2. 3-year clinical outcome of patients with chronic total occlusion treated with drug-eluting stents.
    De Felice F; Fiorilli R; Parma A; Nazzaro M; Musto C; Sbraga F; Caferri G; Violini R
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1260-5. PubMed ID: 20129553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug eluting stents in CTOs: why not?
    Vetrovec GW
    Catheter Cardiovasc Interv; 2011 Feb; 77(3):333-4. PubMed ID: 21328678
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug-eluting stents: safe but not sufficient.
    Vogel RA
    JACC Cardiovasc Interv; 2009 Jun; 2(6):513-4. PubMed ID: 19539254
    [No Abstract]   [Full Text] [Related]  

  • 5. DES in CTO: cosmetic or clinical benefit.
    Goyal BK
    Catheter Cardiovasc Interv; 2009 May; 73(6):780. PubMed ID: 19370758
    [No Abstract]   [Full Text] [Related]  

  • 6. Are we totally clear?
    Morrison DA
    Catheter Cardiovasc Interv; 2009 Dec; 74(7):987-8. PubMed ID: 19953511
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug-eluting stents for ST-segment elevation myocardial infarction: treatment of choice or is discretion the better part of valor?
    Rihal CS
    JACC Cardiovasc Interv; 2008 Jun; 1(3):233-5. PubMed ID: 19463305
    [No Abstract]   [Full Text] [Related]  

  • 8. Are our patients better off with drug-eluting stents in saphenous vein grafts?
    Douglas JS
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1113-5. PubMed ID: 19926053
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study.
    Wijnbergen I; Helmes H; Tijssen J; Brueren G; Peels K; van Dantzig JM; Van' t Veer M; Koolen JJ; Pijls NH; Michels R
    JACC Cardiovasc Interv; 2012 Mar; 5(3):313-22. PubMed ID: 22440498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Left main and high-risk PCI: what, exactly, is it high risk for?
    Safian RD
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):952-3. PubMed ID: 21598347
    [No Abstract]   [Full Text] [Related]  

  • 11. DES in SVGs: safe and at least short-term effective.
    Hillegass WB
    Catheter Cardiovasc Interv; 2011 Feb; 77(3):356-7. PubMed ID: 21328680
    [No Abstract]   [Full Text] [Related]  

  • 12. Paclitaxel-coated balloon with bare-metal stenting in patients with chronic total occlusions in native coronary arteries.
    Wöhrle J; Werner GS
    Catheter Cardiovasc Interv; 2013 Apr; 81(5):793-9. PubMed ID: 22511572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. It's not the dye, but the "die" in dialysis: which coronary revascularization strategy really is best?
    Butman SM
    Catheter Cardiovasc Interv; 2010 Dec; 76(7):949-50. PubMed ID: 21108371
    [No Abstract]   [Full Text] [Related]  

  • 14. Optimizing the impact of primary percutaneous coronary intervention in acute myocardial infarction.
    Satler LF
    Catheter Cardiovasc Interv; 2011 Feb; 77(2):201. PubMed ID: 21290554
    [No Abstract]   [Full Text] [Related]  

  • 15. Outcomes and complications with off-label use of drug-eluting stents: results from the STENT (Strategic Transcatheter Evaluation of New Therapies) group.
    Brodie BR; Stuckey T; Downey W; Humphrey A; Bradshaw B; Metzger C; Hermiller J; Krainin F; Juk S; Cheek B; Duffy P; Smith H; Edmunds J; Varanasi J; Simonton CA;
    JACC Cardiovasc Interv; 2008 Aug; 1(4):405-14. PubMed ID: 19463338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial.
    Holmes DR; Teirstein PS; Satler L; Sketch MH; Popma JJ; Mauri L; Wang HP; Schleckser PA; Cohen SA;
    JACC Cardiovasc Interv; 2008 Aug; 1(4):439-48. PubMed ID: 19463342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late clinical events after drug-eluting stents: the interplay between stent-related and natural history-driven events.
    Leon MB; Allocco DJ; Dawkins KD; Baim DS
    JACC Cardiovasc Interv; 2009 Jun; 2(6):504-12. PubMed ID: 19539253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of percutaneous coronary intervention for chronic total occlusions.
    Mehran R; Claessen BE; Godino C; Dangas GD; Obunai K; Kanwal S; Carlino M; Henriques JP; Di Mario C; Kim YH; Park SJ; Stone GW; Leon MB; Moses JW; Colombo A;
    JACC Cardiovasc Interv; 2011 Sep; 4(9):952-61. PubMed ID: 21939934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. We can build it, but will they come?
    Gilchrist IC
    Catheter Cardiovasc Interv; 2011 May; 77(6):818-9. PubMed ID: 21520383
    [No Abstract]   [Full Text] [Related]  

  • 20. Another small step for small vessels.
    Morrison DA
    Catheter Cardiovasc Interv; 2010 Jul; 76(1):67-9. PubMed ID: 20578195
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.